Listen

National Veterinary Vaccines Company

| Learn about investment opportunities

National Veterinary Vaccines Company

Icon

The company, established in late 2019, aims to contribute to the demand in Arab countries for essential, commonly used vaccines, such as those for livestock foot-and mouth disease, bird flu and Newcastle disease, among others.

Icon

Free Zone Port of Sohar-Sultanate of Oman

Contact address
  • Icon Ghala, Bousher, Muscat Governorate
    (+968) 993 12289
  • Icon ali.alsahmy@nvvco.com
  • Icon P.O. Box 61, Zip code: 134
Icon
Designed capacity

The project will be implemented in two phases:

  • – Phase I: targeting the aseptic filling and production of 114.5 million doses of different vaccines over an expansion plan period of five years
  • – Phase II: production of 144 million doses of different vaccines from year 5 onward

Icon
Capital and shareholders

The Initial capital is OMR 200 thousands, and shareholders are:

  • – Arab Authority for Agricultural Investment and Development: 50%
  • – Oman Food Investment Holding Company: 50%
Icon
Average sales

The company's estimated sales at stability year (the tenth year of production) are estimated at USD 52.7 million

Icon
Market share

The market share is estimated at 12%.

Icon
Company products

- Foot Mouth Disease (FMD) vaccine
- Newcastle vaccine, bird flu vaccine, and others

Icon
Investment cost

The total investment cost is estimated at USD 55.4 million, representing an investment cost of USD 17.36 million at phase I and USD 38.04 million at phase II in addition to initial working capital estimated at USD 2.55 million.

Icon
Financial indicators

  • IRR: 19%
  • Payback period: 5 years and 3 months

Icon
Required finance

- Phase I: 50% equity and 50% loans
- Phase II: 32% equity, 64% loans, and 4% internal finance

Learn about the investment opportunities in: National Veterinary Vaccines Company

01

Participation in equity and/or Provision of loans to complete implementation of project components